Pulse Biosciences, Inc. (PLSE)
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
$53.24-2.69%
Close 2026-09-04 · 1-day change
NASDAQHealth CareMedical - Instruments & SuppliesSnapshot 2026-09-04
Intact: The reason to own it still holds.
Pulse Biosciences is growing revenue from new products. Revenue rose to $401,000 in 2026-Q1. The company hired a new COO to improve operations. A director bought $13 million in stock, showing confidence.
Pulse Biosciences is still losing money and missed earnings recently. Revenue is small and growth uncertain. Key sales officer left, which may hurt sales. Analysts expect losses to continue through 2027.
The market expects continued losses and small revenue growth. There is no clear price target or consensus growth forecast. Our view is cautious due to lack of profitability and uncertain growth.
Breaks if: no insider buying or insider selling increases
Breaks if: no operational improvements or further key departures
This is not a price target or investment advice.
A long-form read on the 1–3 year hold thesis. It updates when the weekly evidence changes.
This investment represents a speculative growth opportunity. The company is currently loss-making and has shown weak recent financial performance, but it operates in a sector that may provide favorable momentum if key players perform well.
The market appears to have low expectations for PLSE, given its recent earnings misses and loss-making status. There is a low fragility tier, indicating that current valuations may not be overly sensitive to immediate changes.
Management is focused on advancing clinical development, but recent financial performance has been weak. Cash flow management remains a concern, with increased spending on clinical programs and limited progress on cost containment.
The long-term thesis hinges on the performance of sector bellwethers like ISRG, BDX, and RMD. If these companies continue to perform well, it could provide a tailwind for PLSE, while any negative shifts could pose risks.
The most important moves since the prior daily snapshot.
Yes, our read has weakened. The latest earnings miss has raised concerns about performance. Additionally, a recent $75 million offering may strain cash flow management efforts.
as of 2026-09-04
Review the evidence to watch, what would become a concern, and what would make it less concerning.
Not investment advice. Scores describe historical and current data; they are not forecasts of future returns. Consult a licensed advisor before making investment decisions.
Breaks if: revenue falls below $400,000 in 2026-Q1
Grow revenue by advancing product development and commercial launch of nPulse Vybrance and other therapies.
Stated in 2 of last 2 quarters (2026-Q1 and 2026-Q2). Revenue from nPulse Vybrance increased sequentially from $0.4 million in 2026-Q1 to $0.434 million in 2026-Q2. This reflects early-stage commercial launch progress and product development efforts, indicating delivering but still limited revenue scale.
“Generated $434 thousand of second quarter revenue, representing sequential growth over the first quarter.”
“Total revenue for the three months ended March 31, 2026 was $0.4 million, including capital and disposable sales.”
Over the next 1 to 3 years, PLSE's outlook will depend heavily on sector dynamics and management execution. Not investment advice.